1
|
Traxler D, Krotka P, Reichardt B, Copic D, Veraar C, Mildner M, Wendt R, Auer J, Mascherbauer J, Ankersmit HJ, Graf A. Revisiting aortic valve prosthesis choice in patients younger than 50 years: 10 years results of the AUTHEARTVISIT study. Eur J Cardiothorac Surg 2024; 65:ezad308. [PMID: 37756697 PMCID: PMC10761203 DOI: 10.1093/ejcts/ezad308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 08/22/2023] [Accepted: 09/22/2023] [Indexed: 09/29/2023] Open
Abstract
OBJECTIVES This population-based cohort study investigated mid-term outcome after surgical aortic valve replacement with a bioprosthetic or mechanical valve prosthesis in patients aged <50 years in a European social welfare state. METHODS We analysed patient data from the main social insurance carriers in Austria (2010-2020). Subsequent patient-level record linkage with national health data provided patient characteristics and clinical outcome. Survival, reoperation, myocardial infarction, heart failure, embolic stroke or intracerebral haemorrhage, bleeding other than intracerebral haemorrhage and major adverse cardiac events were evaluated as outcomes. RESULTS A total of 991 patients were analysed. Regarding demographics, no major differences between groups were observed. Multivariable Cox regression revealed no significant difference in overall survival (P = 0.352) with a median follow-up time of 6.2 years. Reoperation-free survival was decreased (hazard ratio = 1.560 [95% CI: 1.076-2.262], P = 0.019) and the risk for reoperation was increased (hazard ratio = 2.770 [95% CI: 1.402-5.472], P = 0.003) in patients who received bioprostheses. Estimated probability of death after reoperation was 0.23 (CL: 0.08-0.35) after 2 years and 0.34 (CL: 0.06-0.53) after 10 years over both groups. Regarding further outcomes, no significant differences between the two groups were observed. CONCLUSIONS In patients below 50 years of age receiving aortic valve replacement, implantation of bioprostheses when compared to mechanical heart valve prostheses was associated with a significantly higher rate of reoperations and reduced reoperation-free survival. Nevertheless, we could not observe a difference in overall survival. However, long-term follow-up has to evaluate that a significantly lower rate of reoperations may translate in consistently improved long-term survival.
Collapse
Affiliation(s)
- Denise Traxler
- Clinic of Thoracic Surgery, Medical University of Vienna, Austria
- Laboratory for Cardiac and Thoracic Diagnosis, Regeneration and Applied Immunology, Austria
- Department of Oral and Maxillofacial Surgery, Medical University of Vienna, Austria
| | - Pavla Krotka
- Center for Medical Data Science, Medical University of Vienna, Austria
| | | | - Dragan Copic
- Clinic of Thoracic Surgery, Medical University of Vienna, Austria
- Laboratory for Cardiac and Thoracic Diagnosis, Regeneration and Applied Immunology, Austria
- Division of Nephrology and Dialysis, Medical University of Vienna, Austria
| | - Cecilia Veraar
- Laboratory for Cardiac and Thoracic Diagnosis, Regeneration and Applied Immunology, Austria
- Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, Medical University of Vienna, Austria
| | - Michael Mildner
- Department of Dermatology, Medical University of Vienna, Austria
| | - Ralph Wendt
- Department of Nephrology, St. Georg Hospital, Leipzig, Germany
| | - Johann Auer
- Department of Internal Medicine I with Cardiology and Intensive Care, St. Josef Hospital Braunau, Braunau am Inn, Austria
| | - Julia Mascherbauer
- Department of Internal Medicine 3, University Hospital St. Poelten, Austria
| | - Hendrik Jan Ankersmit
- Clinic of Thoracic Surgery, Medical University of Vienna, Austria
- Laboratory for Cardiac and Thoracic Diagnosis, Regeneration and Applied Immunology, Austria
| | - Alexandra Graf
- Center for Medical Data Science, Medical University of Vienna, Austria
| |
Collapse
|
2
|
Ahmed KA, Ahmed J, Samant A, Arub Y, Mohsin I, Ahmed MH. The Longest Known Survival of a Patient With Bioprosthetic Aortic Valve Replacement: A 42-Year Follow-Up. Cureus 2023; 15:e44069. [PMID: 37638273 PMCID: PMC10449611 DOI: 10.7759/cureus.44069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/24/2023] [Indexed: 08/29/2023] Open
Abstract
Aortic valve replacement (AVR) is a frequently performed procedure for treating aortic valvulopathy. AVR involves replacing the damaged aortic valve with either a mechanical or a bioprosthetic valve. While many factors are involved when selecting between the two options, age and patient preference are the deciding factors at this point. Mechanical valves demonstrate long-standing durability that overlaps with the accompanied bleeding risk due to lifetime anticoagulant therapy, making them a more favorable choice for younger patients. Bioprosthetic valves are preferred for older patients as they show a reduced risk of thrombogenicity. However, bioprosthetic valves have a higher incidence of structural valve degeneration (SVD) than mechanical valves. Our case report focuses on a 76-year-old patient who had undergone an AVR with a bioprosthetic valve at the age of 33, which has still not demonstrated any valve deterioration. As the longest known case of bioprosthetic durability, this patient provides useful data for designing bioprosthetic valves more resistant to structural degeneration and thereby better suited to younger patients or those at higher risk of bleeding.
Collapse
Affiliation(s)
| | | | | | - Yusra Arub
- Department of Research, KAAJ Healthcare, San Jose, USA
| | - Ibrahim Mohsin
- Department of Internal Medicine, Norton Community Hospital, Norton, USA
| | | |
Collapse
|
3
|
Grashuis P, Khargi SD, Veen K, el Osrouti A, Bemelmans-Lalezari S, Cornette JM, Roos-Hesselink JW, Takkenberg JJ, Mokhles MM. Pregnancy outcomes in women with a mitral valve prosthesis: A systematic review and meta-analysis. JTCVS OPEN 2023; 14:102-122. [PMID: 37425470 PMCID: PMC10328972 DOI: 10.1016/j.xjon.2023.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 04/26/2023] [Accepted: 05/02/2023] [Indexed: 07/11/2023]
Abstract
Objectives To evaluate the ongoing debate concerning the choice of valve prosthesis for women requiring mitral valve replacement (MVR) and who wish to conceive. Bioprostheses are associated with risk of early structural valve deterioration. Mechanical prostheses require lifelong anticoagulation and carry maternal and fetal risks. Also, the optimal anticoagulation regimen during pregnancy after MVR remains unclear. Methods A systematic review and meta-analysis was conducted of studies reporting on pregnancy after MVR. Valve- and anticoagulation-related maternal and fetal risks during pregnancy and 30 days' postpartum were analyzed. Results Fifteen studies reporting 722 pregnancies were included. In total, 87.2% of pregnant women had a mechanical prosthesis and 12.5% a bioprosthesis. Maternal mortality risk was 1.33% (95% confidence interval [CI], 0.69-2.56), any hemorrhage risk 6.90% (95% CI, 3.70-12.88). Valve thrombosis risk was 4.71% (95% CI, 3.06-7.26) in patients with mechanical prostheses. 3.23% (95% CI, 1.34-7.75) of the patients with bioprostheses experienced early structural valve deterioration. Of these, the mortality was 40%. Pregnancy loss risk was 29.29% (95% CI, 19.74-43.47) with mechanical prostheses versus 13.50% (95% CI, 4.31-42.30) for bioprostheses. Switching to heparin during the first trimester demonstrated a bleeding risk of 7.78% (95% CI, 3.71-16.31) versus 4.08% (95% CI, 1.17-14.28) for women on oral anticoagulants throughout pregnancy and a valve thrombosis risk of 6.99% (95% CI, 2.08-23.51) versus 2.89% (95% CI, 1.40-5.94). Administration of anticoagulant dosages greater than 5 mg resulted in a risk of fetal adverse events of 74.24% (95% CI, 56.11-98.23) versus 8.85% (95% CI, 2.70-28.99) in ≤5 mg. Conclusions A bioprosthesis seems the best option for women of childbearing age who are interested in future pregnancy after MVR. If mechanical valve replacement is preferred, the favorable anticoagulation regimen is continuous low-dose oral anticoagulants. Shared decision-making remains priority when choosing a prosthetic valve for young women.
Collapse
Affiliation(s)
- Pepijn Grashuis
- Department of Cardiothoracic Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Shanti D.M. Khargi
- Department of Cardiothoracic Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Kevin Veen
- Department of Cardiothoracic Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Azzeddine el Osrouti
- Department of Cardiothoracic Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands
| | | | - Jérôme M.J. Cornette
- Department of Obstetrics and Fetal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
| | | | | | - Mostafa M. Mokhles
- Department of Cardiothoracic Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands
- Department of Cardiothoracic Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands
| |
Collapse
|
4
|
Gwak SY, Ko KY, Cho I, Hong GR, Ha JW, Shim CY. Risk factors and outcomes with surgical bioprosthetic mitral valve dysfunction. Heart 2022; 109:63-69. [PMID: 36371666 DOI: 10.1136/heartjnl-2022-321307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Accepted: 08/10/2022] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND There are insufficient data regarding the risk factors associated with valve dysfunction of bioprosthetic valves in the mitral position This study aimed to investigate the factors associated with bioprosthetic mitral valve (MV) dysfunction (MVD). METHODS A total of 245 patients (age 67.2±11.2 years, 74.9% women) who were followed up for more than 5 years after surgical bioprosthetic MV replacement were analysed in the setting of retrospective study design. MVD was defined as an increased mean gradient of >5 mm Hg with limited leaflet motion and/or newly developed MV regurgitation of at least moderate severity on follow-up echocardiography. The clinical outcome was defined as a composite of cardiovascular mortality, redo MV surgery or intervention and heart failure-related hospitalisations. RESULTS During a median of 96.0 months (IQR 67.0-125.0 months), bioprosthetic MVD occurred in 66 (27.6%) patients. Factors associated with bioprosthetic MVD detected by multivariate regression analysis were age at surgery (HR 0.98, 95% CI 0.96 to 0.99, p<0.001), chronic kidney disease (HR 3.27, 95% CI 1.74 to 6.12, p<0.001), elevated mean diastolic pressure gradient >5.5 mm Hg across the bioprosthetic MV early after operation (HR 2.02, 95% CI 1.08 to 3.78, p=0.028) and average haemoglobin level after surgery (HR 0.80, 95% CI 0.67 to 0.96, p=0.015). Patients with bioprosthetic MVD showed significantly poorer clinical outcomes than those without bioprosthetic MVD (log-rank p<0.001). CONCLUSIONS Young age at operation, chronic kidney disease, elevated pressure gradient across the bioprosthetic MV early after surgery and postsurgical anaemia are associated with bioprosthetic MVD. Bioprosthetic MVD is associated with poor clinical outcomes.
Collapse
Affiliation(s)
- Seo-Yeon Gwak
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - Kyu-Yong Ko
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - Iksung Cho
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - Geu-Ru Hong
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - Jong-Won Ha
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - Chi Young Shim
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea
| |
Collapse
|
5
|
Guimaron S, Kalavrouziotis D, Maranda-Robitaille M, Dumont E, Joubert P, Babaki S, Rodés-Cabau J, Mohammadi S. Macroscopic and microscopic features of surgically explanted transcatheter aortic valve prostheses. J Card Surg 2022; 37:3178-3187. [PMID: 35870159 DOI: 10.1111/jocs.16784] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2022] [Revised: 06/12/2022] [Accepted: 06/19/2022] [Indexed: 01/06/2023]
Abstract
OBJECTIVES With the extended indications of transcatheter aortic valve (TAV) replacement (TAVR) to lower-risk patients, there is an increasing number of patients requiring surgical explantation of failed TAV. We sought to describe macroscopic and microscopic features of surgically explanted percutaneous aortic valve prostheses. METHODS Preoperative and surgical characteristic of patients undergoing surgical explantation of TAV were retrospectively analyzed from 2007 to 2020. Surgical and pathologic features of these valves, and outcomes of the surgical valve replacement were described. RESULTS Out of 1764 patients who underwent a TAVR procedure, 21 were operated for TAV failure. Isolated or combined indications for surgery included: significant paravalvular leak (n = 15), delayed prosthesis migration (n = 5), significant increase of trans-TAV gradients (n = 6), and endocarditis (n = 3). Mean time elapsed between TAVR and explantations was 674.9 ± 803.9 days. Macroscopic lesions found on explanted percutaneous valves were severe adhesions to the aorta (n = 10), calcifications (n = 7), leaflet thrombosis (n = 4), and vegetations (n = 3). Except for patients with endocarditis, one or more pathological lesions were found in 15 patients. Pathology analyses on these valves showed fibro-calcific degenerations (n = 12), pannus formation (n = 9), and chronic inflammation (n = 3). One patient (4.8%) died after surgical explantation, and 13 (61.9%) had concomitant procedures. The survival rate at 1 year was 94.4%. CONCLUSIONS Microscopic findings of fibro-calcific leaflet degeneration, and pannus formation in addition to macroscopic calcification and thrombosis present early, (within a mean of 2 years) after TAVR. Further investigation with a higher number of patients and echocardiographic follow-up is warranted.
Collapse
Affiliation(s)
- Samantha Guimaron
- Department of Cardiac Surgery, Quebec Heart and Lung University Institute, Quebec City, Quebec, Canada
| | - Dimitri Kalavrouziotis
- Department of Cardiac Surgery, Quebec Heart and Lung University Institute, Quebec City, Quebec, Canada
| | | | - Eric Dumont
- Department of Cardiac Surgery, Quebec Heart and Lung University Institute, Quebec City, Quebec, Canada
| | - Phillipe Joubert
- Department of Pathology, Quebec Heart and Lung University Institute, Quebec City, Quebec, Canada
| | - Shervin Babaki
- Department of Research, Quebec Heart and Lung University Institute, Quebec City, Quebec, Canada
| | - Josep Rodés-Cabau
- Department of Cardiology, Quebec Heart and Lung University Institute, Quebec City, Quebec, Canada
| | - Siamak Mohammadi
- Department of Cardiac Surgery, Quebec Heart and Lung University Institute, Quebec City, Quebec, Canada
| |
Collapse
|
6
|
Suzuki R, Ito T, Suzuki M, Ohori S, Takayanagi R, Miura S. Trifecta versus Perimount Magna Ease aortic valves: Failure mechanisms. Asian Cardiovasc Thorac Ann 2022; 30:797-806. [PMID: 35603636 PMCID: PMC9373186 DOI: 10.1177/02184923221100994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Background There are increasing reports of early externally mounted pericardial Trifecta
bioprosthesis failure. We compared the hemodynamic performance of Trifecta
and Carpentier–Edwards Perimount Magna Ease valves to determine the failure
mechanism. Methods We retrospectively included 270 consecutive patients (age: 73.4 ± 8.2 years;
57.5% male; mean follow-up: 48.0 ± 20.3 months) who underwent aortic valve
replacement from 2014 to 2021 at a single center and compared the Trifecta
(N = 137) and Carpentier–Edwards Perimount Magna Ease
valve (N = 133) patients. Results The prosthetic valve major aortic regurgitation incidence was higher for the
Trifecta than that for the Carpentier–Edwards Perimount Magna Ease valve
(6.3% vs. 0%, P < 0.009). Among the Trifecta failures,
33% developed structural valve deterioration, but all requiring redo aortic
valve replacement developed major prosthetic valve aortic regurgitation.
Freedom at 5 years from redo aortic valve replacement due to structural
valve deterioration was significantly lower for Trifecta (89.4% vs. 100%,
P = 0.003). The reoperation hazards were determined for
Trifecta (vs. Carpentier–Edwards Perimount Magna Ease): 11.6 (1.47–90.9;
P = 0.02), prosthetic valve aortic regurgitation: 2.38
(1.70–3.32; P < 0.01), structural valve deterioration:
20.82 (4.08–106.2; P < 0.01), 5-year mean
transprosthetic pressure gradient: 1.14 per 1-point increase (1.03–1.24;
P = 0.007), and urgent surgery: 10.1 (2.59–39.0;
P = 0.001). The Cox regression analysis identified that
prosthetic valve aortic regurgitation solely contributed to redo aortic
valve replacement (hazard ratio: 2.38; confidence intervals: 1.70–3.32). Conclusions Significantly, more early failures occurred with the Trifecta valve than the
Carpentier–Edwards Perimount Magna Ease valve but the Trifecta showed
reasonable mean transprosthetic pressure gradient over time. Prosthetic
valve aortic regurgitation and calcific structural valve deterioration
synergistically contributed to Trifecta valve failure alternatively.
Collapse
Affiliation(s)
- Ryo Suzuki
- Department of Cardiovascular Surgery, Hokkaido Ohno Memorial Hospital, Hokkaido, Japan
| | - Toshiro Ito
- Department of Cardiovascular Surgery, Hokkaido Ohno Memorial Hospital, Hokkaido, Japan
| | - Masato Suzuki
- Department of Cardiovascular Surgery, Hokkaido Ohno Memorial Hospital, Hokkaido, Japan
| | - Shunsuke Ohori
- Department of Cardiovascular Surgery, Hokkaido Ohno Memorial Hospital, Hokkaido, Japan
| | - Ryo Takayanagi
- Department of Cardiovascular Surgery, Hokkaido Ohno Memorial Hospital, Hokkaido, Japan
| | - Shiro Miura
- Department of Cardiovascular Surgery, Hokkaido Ohno Memorial Hospital, Hokkaido, Japan
| |
Collapse
|
7
|
Traxler D, Krotka P, Laggner M, Mildner M, Graf A, Reichardt B, Wendt R, Auer J, Moser B, Mascherbauer J, Ankersmit HJ. Mechanical aortic valve prostheses offer a survival benefit in 50-65 year olds: AUTHEARTVISIT study. Eur J Clin Invest 2022; 52:e13736. [PMID: 34932232 PMCID: PMC9285970 DOI: 10.1111/eci.13736] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Revised: 12/17/2021] [Accepted: 12/18/2021] [Indexed: 12/15/2022]
Abstract
BACKGROUND The present population-based cohort study investigated long-term mortality after surgical aortic valve replacement (AVR) with bioprosthetic (B) or mechanical aortic valve prostheses (M) in a European social welfare state. METHODS We analysed patient data from health insurance records covering 98% of the Austrian population between 2010 and 2018. Subsequent patient-level record linkage with national health data provided patient characteristics and clinical outcomes. Further reoperation, myocardial infarction, heart failure and stroke were evaluated as secondary outcomes. RESULTS A total of 13,993 patients were analysed and the following age groups were examined separately: <50 years (727 patients: 57.77% M, 42.23% B), 50-65 years (2612 patients: 26.88% M, 73.12% B) and >65 years (10,654 patients: 1.26% M, 98.74% B). Multivariable Cox regression revealed that the use of B-AVR was significantly associated with higher mortality in patients aged 50-65 years compared to M-AVR (HR = 1.676 [1.289-2.181], p < 0.001). B-AVR also performed worse in a competing risk analysis regarding reoperation (HR = 3.483 [1.445-8.396], p = 0.005) and myocardial infarction (HR = 2.868 [1.255-6.555], p = 0.012). However, the risk of developing heart failure and stroke did not differ significantly after AVR in any age group. CONCLUSIONS Patients aged 50-65 years who underwent M-AVR had better long-term survival, and a lower risk of reoperation and myocardial infarction. Even though anticoagulation is crucial in patients with M-AVR, we did not observe significantly increased stroke rates in patients with M-AVR. This evident survival benefit in recipients of mechanical aortic valve prostheses aged <65 years critically questions current guideline recommendations.
Collapse
Affiliation(s)
- Denise Traxler
- Division of CardiologyDepartment of Internal Medicine IIMedical University of ViennaViennaAustria
- Laboratory for Cardiac and Thoracic Diagnosis, Regeneration and Applied ImmunologyViennaAustria
- Department of Thoracic SurgeryMedical University of ViennaViennaAustria
| | - Pavla Krotka
- Center for Medical StatisticsInformatics and Intelligent SystemsMedical University of ViennaViennaAustria
| | - Maria Laggner
- Laboratory for Cardiac and Thoracic Diagnosis, Regeneration and Applied ImmunologyViennaAustria
- Department of Thoracic SurgeryMedical University of ViennaViennaAustria
| | - Michael Mildner
- Department of DermatologyMedical University of ViennaViennaAustria
| | - Alexandra Graf
- Center for Medical StatisticsInformatics and Intelligent SystemsMedical University of ViennaViennaAustria
| | | | - Ralph Wendt
- Department of Infectious DiseasesTropical Medicine, Nephrology and RheumatologySt. Georg HospitalLeipzigGermany
| | - Johann Auer
- Department of Internal Medicine I with Cardiology and Intensive CareSt. Josef Hospital BraunauBraunau am InnAustria
| | - Bernhard Moser
- Department of Thoracic SurgeryMedical University of ViennaViennaAustria
| | - Julia Mascherbauer
- Department of Internal Medicine 3University Hospital St. PoeltenSt. PoeltenAustria
- Karl Landsteiner University of Health SciencesKrems an der DonauAustria
| | - Hendrik Jan Ankersmit
- Laboratory for Cardiac and Thoracic Diagnosis, Regeneration and Applied ImmunologyViennaAustria
- Department of Thoracic SurgeryMedical University of ViennaViennaAustria
| |
Collapse
|